SI2001456T1 - Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni - Google Patents

Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni

Info

Publication number
SI2001456T1
SI2001456T1 SI200730163T SI200730163T SI2001456T1 SI 2001456 T1 SI2001456 T1 SI 2001456T1 SI 200730163 T SI200730163 T SI 200730163T SI 200730163 T SI200730163 T SI 200730163T SI 2001456 T1 SI2001456 T1 SI 2001456T1
Authority
SI
Slovenia
Prior art keywords
treatment
opioid receptor
receptor antagonist
kappa opioid
containing compositions
Prior art date
Application number
SI200730163T
Other languages
English (en)
Slovenian (sl)
Inventor
Lars-Holger Dr Hermann
Original Assignee
Emodys Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys Gmbh filed Critical Emodys Gmbh
Publication of SI2001456T1 publication Critical patent/SI2001456T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI200730163T 2006-04-04 2007-04-03 Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni SI2001456T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
EP07727719A EP2001456B1 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
SI2001456T1 true SI2001456T1 (sl) 2010-04-30

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730163T SI2001456T1 (sl) 2006-04-04 2007-04-03 Uporaba zmesi, ki vsebuje antagonist na opioidnem kapa receptorju za zdravljenje disocialnih bolezni

Country Status (17)

Country Link
US (1) US8063059B2 (enExample)
EP (1) EP2001456B1 (enExample)
JP (1) JP5128578B2 (enExample)
AT (1) ATE450256T1 (enExample)
AU (1) AU2007236003B2 (enExample)
CA (1) CA2646899C (enExample)
CY (1) CY1109862T1 (enExample)
DE (1) DE502007002185D1 (enExample)
DK (1) DK2001456T3 (enExample)
EA (1) EA014820B1 (enExample)
ES (1) ES2337622T3 (enExample)
HR (1) HRP20100113T1 (enExample)
PL (1) PL2001456T3 (enExample)
PT (1) PT2001456E (enExample)
RS (1) RS51211B (enExample)
SI (1) SI2001456T1 (enExample)
WO (1) WO2007115975A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2797B1 (en) 2008-01-22 2014-03-15 ايلي ليلي اند كومباني Selective opioid receptor antagonist kappa
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
AU2014368548B2 (en) * 2013-12-20 2019-09-19 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN106470999B (zh) 2014-04-28 2018-11-13 奥佛麦德公司 叔丁啡二聚体及其在治疗肠胃失调中的应用
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
EP1061924A1 (en) * 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
US20020045572A1 (en) * 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
WO2002013759A2 (en) 2000-08-15 2002-02-21 Cpd Llc Method of treating the syndrome of type 2 diabetes in humans
EP1353665A4 (en) * 2000-12-21 2004-05-06 Mclean Hospital Corp Treatment of depression
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7268151B2 (en) * 2003-04-04 2007-09-11 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
WO2005084654A2 (en) 2004-03-02 2005-09-15 Pharmacia Corporation Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
ATE462704T1 (de) * 2004-05-26 2010-04-15 Inotek Pharmaceuticals Corp Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür
DE602004017514D1 (de) 2004-06-02 2008-12-11 Galephar M F Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Also Published As

Publication number Publication date
EA014820B1 (ru) 2011-02-28
EA200802104A1 (ru) 2009-04-28
EP2001456B1 (de) 2009-12-02
PT2001456E (pt) 2010-03-03
DE502007002185D1 (de) 2010-01-14
JP5128578B2 (ja) 2013-01-23
PL2001456T3 (pl) 2010-05-31
US8063059B2 (en) 2011-11-22
WO2007115975A2 (de) 2007-10-18
HRP20100113T1 (hr) 2010-04-30
EP2001456A2 (de) 2008-12-17
CY1109862T1 (el) 2014-09-10
WO2007115975A3 (de) 2008-02-14
JP2009532434A (ja) 2009-09-10
ATE450256T1 (de) 2009-12-15
CA2646899A1 (en) 2007-10-18
RS51211B (sr) 2010-12-31
CA2646899C (en) 2014-05-06
AU2007236003A1 (en) 2007-10-18
DK2001456T3 (da) 2010-04-12
ES2337622T3 (es) 2010-04-27
AU2007236003B2 (en) 2012-10-18
US20090181999A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
IL208895A0 (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
NZ594140A (en) C5ar antagonists
PL2001456T3 (pl) Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
IL201790A0 (en) Pyridyl piperidine orexin receptor antagonists
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
ZA200710611B (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
PL2049529T3 (pl) Podstawione związki diazepanowe - antagoniści receptora oreksyny
PT1729753E (pt) Utilização de um antagonista dos receptores de nmda para o tratamento de zumbido induzido por excitotoxicidade coclear
PT2001876E (pt) Compostos de 8-azabiciclo[3.2.1]octano como antagonistas do receptor opióide mu
MX2009004662A (es) Compuestos de pirazolina como antagonistas receptores de mineralocorticoides.
EP2170064A4 (en) 6,5-pyrrolopiperidine tachykinin receptor antagonists
PL2238110T3 (pl) Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
EP2075252A4 (en) NK1 Receptor Antagonists COMPOSITION
EP1899318A4 (en) NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
ZA200607159B (en) Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
ZA200900613B (en) 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonist for the treatment of CNS disorders
ZA200808463B (en) Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders
ZA200705524B (en) Synthesis of CCR5 receptor antagonists
MX2009006313A (es) Antagonistas v3 para el tratamiento o prevencion de dolor cronico.
HK1127349A (en) 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders
HK1155643A (en) Nmda receptor antagonists for the treatment of neuropsychiatric disorders
ZA200906849B (en) Mineralcorticoid receptor antagonists for the treatment of endomertriosis